June 10, 2019
Soliqua®Phase 3 results significantly lowered blood sugar levels compared to GLP-1 receptor agonist treatments
Soliqua®Phase 3 results significantly lowered blood sugarlevels compared to GLP-1 receptor agonist treatmentsPatients switched to Soliqua reached anaverage blood sugarbelowthe American Diabetes Association recommendedlevel of 7%FullPhase 3 data presentedtodayat the American Diabetes Association(ADA)79th Scientific Sessions PARIS–June 9, 2019–In a Phase 3 study1evaluating adults with type 2 diabetes inadequately controlled by GLP-1 receptor agonist (GLP-1 RA) […]
Read More


